Page 1,111«..1020..1,1101,1111,1121,113..1,1201,130..»

BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any…

Posted: March 4, 2020 at 10:44 pm

TEL AVIV, Israel, Feb. 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of motixafortide (BL-8040), a novel immunotherapy compound, combined with any PD-1 inhibitor, for the treatment of any type of cancer.

The PD-1 antagonist can be any agent that prevents and/or inhibits the biological function and/or expression of PD-1, such as pembrolizumab (KEYTRUDA). The targeted cancer can be solid, non-solid, and/or a cancer metastasis.

This patent, whenmedi issued, will be valid until July 2036 with a possibility of up to five years patent term extension. Additional corresponding patent applications are pending in Europe, Japan, China, Canada, Australia, India, Korea, Mexico, Brazil and Israel.

"We are extremely pleased to receive this valuable notice of allowance from the USPTO, which entitles us to long-term, highly enforceable and broad patent protection for our lead product, motixafortide, in combination with any PD-1 inhibitor, and more importantly, for all cancer indications, including, of course, any solid tumor," stated Philip Serlin, Chief Executive Officer of BioLineRx. "This important patent allowance also supports our ongoing Phase 2a COMBAT/KEYNOTE-202, for which we have recently completed patient recruitment in the triple combination arm investigating the safety, tolerability and efficacy of motixafortide, KEYTRUDA and chemotherapy. Following promising initial results demonstrating robust and durable responses to the triple combination treatment, we look forward to the progression-free and overall survival data from the triple combination arm expected in mid-2020."

The COMBAT/KEYNOTE-202 Study

The Phase 2a COMBAT/KEYNOTE-202 study was originally designed as an open-label, multicenter, single-arm trial to evaluate the safety and efficacy of the dual combination of motixafortideand KEYTRUDA (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, N.J., USA (known as MSD outside the United States and Canada), in over 30 subjects with metastatic pancreatic adenocarcinoma. The study was primarily designed to evaluate the clinical response, safety and tolerability of the combination of these therapies, and was carried out in the US, Israel and additional territories. The study is being conducted by BioLineRx under a collaboration agreement signed in 2016 between BioLineRx and MSD, through a subsidiary.

In July 2018, the Company announced the expansion of its immuno-oncology collaboration with MSD to include the triple combination arm investigating the safety, tolerability and efficacy of motixafortide, KEYTRUDA and chemotherapy as part of the Phase 2a COMBAT/KEYNOTE-202 study. In January 2020, the Company announced completion of recruitment of the 40 patients planned for the triple combination arm of the study.

About Motixafortide in Cancer Immunotherapy

Motixafortideis targeting CXCR4, a chemokine receptor and a well validated therapeutic target that is over-expressed in many human cancers including PDAC. CXCR4 plays a key role in tumor growth, invasion, angiogenesis, metastasis and therapeutic resistance, and CXCR4 overexpression has been shown to be correlated with poor prognosis.

Motixafortideis a short synthetic peptide used as a platform for cancer immunotherapy with unique features allowing it to function as a best-in-class antagonist of CXCR4. It shows high-affinity, long receptor occupancy and acts as an inverse agonist.

In a number of clinical and preclinical studies, motixafortidehas been shown to affect multiple modes of action in "cold" tumors, including immune cell trafficking, tumor infiltration by immune effector T cells, and reduction in immunosuppressive cells (such as MDSCs) within the tumor niche, turning "cold" tumors, such as pancreatic cancer, "hot" (i.e., sensitizing them to immune checkpoint inhibitors and chemotherapy).

About BioLineRx

BioLineRx Ltd. (NASDAQ: BLRX), (TASE: BLRX) is a clinical-stage biopharmaceutical company focused on oncology. The Company's business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

The Company's lead program, motixafortide, is a cancer therapy platform currently being evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA and chemotherapy under a collaboration agreement with MSD. Motixafortideis also being evaluated in a Phase 2b study in consolidation AML and a Phase 3 study in stem cell mobilization for autologous bone-marrow transplantation.

BioLineRx is developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently being investigated in a Phase 1/2a study.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook,Twitter, and LinkedIn.

Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 28, 2019. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

Contact:

Tim McCarthyLifeSci Advisors, LLC+1-212-915-2564[emailprotected]

or

Tsipi HaitovskyPublic Relations+972-52-598-9892[emailprotected]

SOURCE BioLineRx Ltd.

http://www.biolinerx.com

See the article here:
BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any...

Posted in New Mexico Stem Cells | Comments Off on BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any…

2020-2025 Global and Regional Hormone Replacement Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research…

Posted: March 4, 2020 at 9:46 am

The global Hormone Replacement Therapy market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Hormone Replacement Therapy market, offers profound understandings about the Hormone Replacement Therapy market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Hormone Replacement Therapy focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4361241

Manufacturer Detail

By Market Players:F. Hoffmann-La Roche, Novartis, Novo Nordisk, Amgen, ANI Pharmaceuticals, Bayer, Eli Lilly, Hisamitsu Pharmaceutical, Ipsen, Merck, Mylan Laboratories, Orion, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries, TherapeuticsMD

By Application

By TypeEstrogen Replacement Therapy, Growth Hormone Replacement Therapy

The Hormone Replacement Therapy market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Hormone Replacement Therapy market. This report on Hormone Replacement Therapy has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Hormone Replacement Therapy research study by HNY Research offers collection of information and analysis for each facet of the Hormone Replacement Therapy market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-hormone-replacement-therapy-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Hormone Replacement Therapy report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4361241

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Read more from the original source:
2020-2025 Global and Regional Hormone Replacement Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research...

Posted in Hormone Replacement Therapy | Comments Off on 2020-2025 Global and Regional Hormone Replacement Therapy Industry Production, Sales and Consumption Status and Prospects Professional Market Research…

Sex Column: Trans rights are the next big step toward equality in Ireland – hotpress.com

Posted: March 4, 2020 at 9:46 am

Ireland has come a long way over the past few decades, in relation to respecting the rights of the LGBTQ+ community. But there is a lot more to be done in the area, especially in relation to Trans rights

The question came up in conversation with friends recently. The more I thought about it afterwards, the more convinced I was that it was incredibly important to use this column to talk about the issue.

With that in mind, I had the absolute pleasure of sitting down with Lilith Keeva Carroll who works as the National Community Development Officer with TENI and talking to her not just about her own experiences, but also about trans rights in general. It turned out to be a very educational conversation indeed.

From the start of our conversation, I am struck by the strength it must take to stand up and speak your truth when society isnt ready to acknowledge or could even be fighting against you. Lilith came out as transgender at the age of 31, She recalls having to block out the noise of society telling me who I should and shouldnt be; and battling against the rigid gender roles that are thrown at all of us.

Lilith speaks fascinatingly about the start of her transition and the new challenges with which she was faced. I now moved through the world in a different way, she recalls. I was doing at 31 what girls did when they were 12: trying to figure out what works for you and learning things you previously werent able or allowed to do.

There was a difference too in the way other people saw Lilith. Theres a change in the worlds perception of you, she observes, moving from the feeling of erasure to then having to grapple with hyper-visability, where people would now read me as a woman, or a trans-woman, or I could even be misgendered.

Im interested to hear about the kind of help and support provided for trans people within the Irish healthcare system. How does Lilith rate it? The models of healthcare that exist in Ireland are quite regressive, she says. When you look at the likes of Argentina, they have a much more progressive model in terms of healthcare and informed consent. You just have to look at the waiting lists and the personal testimonies of trans people, and their experiences with our healthcare, to see that its a real struggle.

Lilith points out that, while top surgery (breast augmentation) is available for trans women, its equivalent for trans men (mastectomy) is not. As a result, the option of transitioning surgically represents a huge challenge in Ireland. Where relevant, trans people have to seek these operations elsewhere and, with the cost of surgery and travel starting around 10,000 but often running considerably higher a lot of trans people (including Lilith) have to turn to fundraising for their own healthcare.*When you look at the economic status of trans people, its incredibly low, Lilith says, and so a lot of people are stuck with this system, which acts as a barrier to their bodily autonomy. In Ireland, there are parallels between abortion rights, and the policing of womens bodies in that regard, and trans peoples bodily autonomy and the policing of their bodies in society, either legally or institutionally.

Talking to Lilith, I have to think hard, again and again, about who is making these decisions around trans bodies? Who is creating the hoops that trans people have to jump through? Not me, Lilith laughs.

What she really means, of course, is that trans people are not involved in a decision-making process that hugely affects their lives and their well-being. The reality is that, whether they are seeking hormone replacement therapy or making a completely unrelated visit, serious barriers exist that block trans people from receiving the health care they need and deserve. Lilith explaines that, in reaction to this, the community has had to take on the responsibility of providing support and information to trans people.

Dealing with the health system, there isnt a clear path, she says, so unfortunately it falls back onto the community to give each other tips and to share our experiences. At TENI we do the best we can to provide the information where the healthcare, education and sex education systems have failed. But putting that responsibility on the community does come with risks. Transitioning is a hard process anyway, but (its even more so) if you are struggling with your mental health or with being disabled. Or in direct provision or battling homelessness.

The issues that affect wider society, hit trans people hard, particularly around housing and immigration. If you are an immigrant or person of colour or sex worker, these barriers that block trans people become even greater.

All of these difficulties notwithstanding, Lilith still speaks positively about the role Ireland might take on, when it comes to the progression of trans rights globally. In this, she has been encouraged by the support she found within the feminist community in Ireland, compared to the UK and the USA.

The approach here is inclusive and not based on colonialism, she says. A lot of the ideas of what a woman is supposed to be stems from a colonial past, that doesnt exist in Ireland. I guess the best example of that was the TERFs Out movement around the time of Repeal, when UK feminists were coming over and attempting to impose their very singular feminist views and it just wasnt accepted here.

Transphobic attacks are more common in the UK and the USA than they are in Ireland and transphobic views can often find their way into the ideology of feminist groups. I ask Lilith how we might make sure these things dont happen here.You see the young people that are coming in and thats hopeful, exciting and encouraging, she says. Its about defending that and making sure that it doesnt get rolled back with the discourse that is happening either side of us. With the rise of the far-right (across the world), its important for us not to fuel or feed into that here. And if we dont feed into it, then Ireland could lead the way for trans-rights.

Progressive legislative changes have already been introduced in Ireland, including both the right to correct your gender on your passport; and recognising 16 and 17 year-olds transgender rights, provided they have the support of their parents. However, serious issues and challenges remain: for example, the law still doesnt recognise the rights of non-binary people or trans people under the age of 16.

As we come to the end of our conversation, I too feel the hope that Lilith expresses about the potential for progress on trans rights in Ireland. She makes an analogy between the erasure that trans people have felt and the erasure that Ireland experienced as a country. Asserting a belief in trans rights is very much linked to Irish cultural identity, she insists. Our feminism is so strong here because we have had to fight for our rights against the Catholic Church and our colonial past. Irish people have had to fight for everything and, as a result, we know what we can achieve. There is still work to be done and, as a country, we need to address the sweep it under the carpet culture that allows us to ignore issues.But I am really hopeful that Ireland can lead the way, she concludes. We are now in a place where we can define our future for ourselves, and carve out a space for the trans community and trans rights in Ireland.

You can find Liliths fundraiser here: gofundme.com/f/keeva039s-surgery-fund

View original post here:
Sex Column: Trans rights are the next big step toward equality in Ireland - hotpress.com

Posted in Hormone Replacement Therapy | Comments Off on Sex Column: Trans rights are the next big step toward equality in Ireland – hotpress.com

Mums migraines, anxiety & palpitations were driving her crazy for two years until she was diagnosed with p – The Sun

Posted: March 4, 2020 at 9:46 am

CLAIRE Dunwell thought she was going crazy when, after turning 40, she began to suffer heart palpitations, migraines and crippling anxiety.

After going back and forth to her GP, she was given medication for anxiety, beta-blockers for her heart and even sent for an ECG heart check.

6

Claire, 42, now knows she is going through the perimenopause, a phase before menopause when hormone levels can fluctuate. She is now undergoing hormone replacement therapy to ease the effects. But it should all have been diagnosed sooner.

A Mumsnet poll found one in four women with menopausal symptoms sees a GP three times before getting the right help. One in four is told she is too young to be perimenopausal.

Here, Claire, a writer who lives in Wakefield, West Yorks, with husband Ian, 55, a chip shop owner, and sons Sam, 13, and Louie, ten shares her story.

SOAKING up the rays, I should have been living my best life.

It was last August, blazing hot, and we were halfway through a two-week family holiday in Crete.

6

While my husband Ian had his head buried in a book, planning his next trip to the all-inclusive bar, I was frantically searching Google on my phone, hoping for answers to explain the way I was feeling.

Since hitting 40 the previous February, I had been plunged into a dark, unfamiliar world.

I had become anxious, irritable and zapped of energy.

When my head wasnt thick with brain fog it throbbed with migraines, and trying to concentrate on anything for longer than half an hour had become a battle.

I felt like someone I didnt recognise not the fun, happy-go-lucky person I was in my carefree twenties and thirties.

6

Id always been fit, healthy and a cup half full kind of girl.

I exercised three times a week, ate healthily and was incredibly lucky to have a loving husband, two healthy children, great friends and a successful career.

From the outside looking in, I had it all.

But on the inside, I had suddenly lost control.

Even the most mundane jobs such as unloading the washing machine and trying to pair up socks overwhelmed me.

FACT:

1 in 4 women with symptoms have to see GP 3 times to get right help

Headaches, fatigue, anxiety and palpitations made matters worse.

It was three months after I turned 40 when the repeat trips to my GP surgery began.

I beat myself up for wasting precious NHS time.

I felt like a fledgling hypochondriac.At each visit, doctors tried hard to treat my list of ailments but nothing worked for long.

6

For the migraines, which Id never suffered before and became so unbearable I struggled to hold conversation and just wanted to sleep, a doctor prescribed Sumatriptan.

I took it when the migraines hit and although they helped with the head pain, they made me feel sick and groggy.

At another appointment, this time with a nurse, it was suggested I try a high dose of aspirin as soon as I felt a migraine coming.

If that didnt work, she would refer me to a local migraine support group.

Next came the unexplained anxiety and heart palpitations, which were at their worst during the two weeks before my period.

FACT:

A quarter are told they are too young to be premenopausal

Some days, I felt as though I was going crazy.

I could be enjoying coffee with a friend one minute and gripped by an irrational panic the next.

My heart raced, worrying something terrible was about to happen.

My husband took the brunt of my bad moods.

I felt exhausted all the time because nodding off on the sofa by 9pm most nights meant I struggled to get a good nights sleep.

I was less tolerant with the kids too.

All of this was completely out of character.

Despite the odd night every few weeks when I woke up in the night drenched in sweat, it never dawned on me that it could be down to my hormones.

6

Sobbing to my GP at yet another appointment, I was prescribed Citalopram, an anti-anxiety medication which I hoped could be a magic pill.

I was desperate to try anything.

They even gave me an ECG for the palpitations, but it showed my heart was perfectly normal.

Its only now, looking back, that I realise it was around this time my periods changed.

Some months they were lighter than normal and others they were shorter in length.

Neither me, nor my GP, made the link that I could be heading towards The Change.

It was during that family holiday to Crete last year that I finally reached the end of my tether.

I was six months into the Citalopram but because it wasnt making any difference, I stopped it.

FACT:

The average woman hits menopause at age 51

I made another appointment with my GP and was handed a prescription for beta blockers which slow the heart rate and can help with anxiety.

Instead, they left me feeling spaced out and sluggish, so I could only take them at night.

It was during my son Louies routine asthma check-up last September when everything began to fall into place.

Tearful, I begged a friendly nurse for five minutes of her time.

Youre not going crazy, she reassured me, as I blurted everything out.

Youre perimenopausal.

The nurse said how all my symptoms were likely to be down to a drop in my hormone levels.

At first, the idea seemed ridiculous.

I was 41, and the average age women reach menopause when regular periods stop is 51.

But the more I pieced together my sudden onset of symptoms, the more it made sense.

When I asked if there was a blood test I could have to check my hormone levels, I was told it would be difficult to get a reliable result because hormones fluctuate daily.

The nurse prescribed the mini Pill hoping the top-up of progesterone would help. She suggested trying oestrogen later.

6

I went away feeling both relieved and confident that I was finally on the right path.But while the mini Pill helped with the migraines and eased the anxiety, it caused frequent heavy bleeding.

I was determined to find another solution, so I tracked down Dr Louise Newson, a GP specialising in menopause, and author of the Haynes Menopause Manual.

At her clinic in Stratford-upon-Avon she talked through my symptoms and I was given a blood test which found I had low levels of both oestrogen and testosterone.

While Louise said my results suggested I was perimenopausal, she stressed it is better to go on a patients symptoms than blood tests alone.

Hormone levels change all the time, she told me.

We could do three tests on three consecutive days and get completely different results, so the most important part of the diagnosis is the history from the patient.

When Louise went on to explain how it is not unusual for some women to experience menopausal symptoms up to a decade before The Change, I felt a huge weight lift.

Louise explained: Without hormones, its like trying to drive a car without oil.

The menopause occurs because our ovaries run out of eggs and stop producing hormones.

Many women find that their hormone levels start reducing several years before this.

Louise said that the perimenopause could be just as mentally and physically draining as the real thing.

Your age is key to diagnosis

THE average woman experiences the menopause when regular periods stop aged 51. But hormone levels can fluctuate several years earlier and in some people this can have side-effects.

This is known as the perimenopause.

Dr Louise Newson, pictured, says: Most women get some symptoms linked to changing hormone levels during perimenopause.

Some have symptoms for a decade before the menopause. Guidance from the National Institute for Health and Care Excellence (Nice) says that if a woman is over 45, we dont need to test for perimenopause or menopause.

If theyre 40 to 45 tests can be useful, and if theyre under 40 its important to get a diagnosis. In these situations a woman experiencing menopausal symptoms should seek help and advice from a doctor who specialises in the menopause.

Cells in our hearts, brains, bones, muscles, bladders and blood vessels respond to oestrogen so when levels reduce, all kinds of symptoms can ensue.

My hot flushes, night sweats, low mood, anxiety, joint pains, headaches and even my reduced libido could all be attributed to this fluctuation.

Low testosterone levels can also lead to brain fog, low energy, reduced stamina and reduced libido.

In my case, Louise prescribed an oestrogen gel as well as progesterone tablets, a type of Hormone Replacement Therapy.

She told me: The only way to find out if a drop in hormones is causing the symptoms is by replacing them and then seeing what happens.

The guidelines are very clear that for the majority of women who take HRT, the benefits outweigh the risks.

The menopause needs to be seen as a long-term female hormone deficiency rather than just a natural process that causes symptoms.

By replacing these hormones, we can really improve our future health as well as our symptoms.

I never imagined Id be taking HRT at the age of 42, but I could not contemplate going on for several more years feeling like I had been.

Four weeks into the treatment, Ive found it has already made a huge difference.

SHOW DOWNMum's pristine pad is so perfect she's been accused of stealing show home snaps

Exclusive

MUM IN A MILLIONI fostered a 15-year-old girl at just 22 - then made her my bridesmaid

DETTOL DIPMum-of-two has a DETTOL bath once a week and gives her son, 8, one

AGONISINGThe coil nearly killed me after it became embedded in my womb & triggered sepsis

BEAUTY DOESN'T FADE'Most Beautiful Girl in the World' Thylane Blondeau stuns fans at 18

A BRIT STRANGENew blue passport sparks debate for something odd can you spot it?

Continued here:
Mums migraines, anxiety & palpitations were driving her crazy for two years until she was diagnosed with p - The Sun

Posted in Hormone Replacement Therapy | Comments Off on Mums migraines, anxiety & palpitations were driving her crazy for two years until she was diagnosed with p – The Sun

GoFundMe set up for East Lothian transwoman’s breast augmentation raises over 700 in 24 hours – Edinburgh News

Posted: March 4, 2020 at 9:46 am

The 21 year old make up artist has been overwhelmed by the massive response

A GoFundMe page set up on Thursday has raised more than 700 towards breast augmentation surgery for a transwoman.

Jamie Scott, a makeup artist from Prestonpans, was shocked when she found out that her two bosses had set up the page to help her through her transition.

The total amount being raised has a 6000 target towards the life changing surgery.

Joleen Clark, the organiser wrote: Our beautiful Jamie is the very talented MUA at our salon, Beyond the Mirror hair and beauty in the lovely coastal town of Musselburgh.

Jamie has struggled with her gender identity from when she was old enough to remember, and has had to face many challenges and hurdles on her journey.

Three years ago, Jamie started her transitioning from male to female with the love and support of her family and friends, however this has never been an easy process.

At the moment NHS Scotland require people living with gender dysphoria to have a lived experience of their gender for at least 12 months before hormone replacement therapy is given, but in many cases it can take longer.

For Jamie, it took over two years for the hormones to be approved and released to her by her doctor.

The post continued: Due to the tragic passing of a beautiful young transgender lady in our community we - Amy and Joleen, Jamies bosses - decided we wanted to help Jamie on her journey.

We want to see this most beautiful person feel like the amazing woman she is. Jamie is the most loving, generous, funny, witty lady with the biggest heart so we are asking you, our local community to help make a difference in this lovely ladies life by helping her have breasts which we know would mean the absolute world to her.

21-year-old Jamie said: Im from a tiny little coastal town called Prestonpans and I started transitioning when I was 19.

There has always been judgement, where Im from theres barely anyone like me, its been hard. Im unhappy with my body and I dont feel like myself, my body isnt what it should be.

I expressed it to my bosses and they contacted my family first before they created the fundraiser, I am completely overwhelmed by it.

However, the GoFundMe page has not come without controversy and backlash, she has been subjected to messages stating that she does not deserve the money being donated and it should go to other causes.

Its been horrible, Jamie said, Prestonpans isnt a place for people like me and it is hard.

She described her condition as seeing a stranger when she looks in the mirror and feeling trapped in the wrong body.

Theres a lot of judgement, Jamie continued, A lot of people in the area stare, even people Ive known for years who knew me before I began transitioning and knew I was going through this still look, but I feel dishonest being in my own body. I wake up and I dont feel like myself, going through with the survery will change my life, it will be like a sense of being set free.

The fundraiser has a 6000 target, and her bosses have told her they will help as much as they can, with donations and tips to go towards the end goal.

Jamie said: People cant judge the journey im on unless theyve experienced it themselves, everyone battles their own thing and Ive always fought this by myself.

The number of trans people has tripled and it is making it harder for people to get help, it is just a waiting game.

What I would tell young people who felt like me today is that they need to fight to be themselves but it is a worthwhile fight.

To help other transwomen in the community, Jamie along with her salon now run a trans night, which encourages trans people, who may not be confident enough to visit a salon during the day to come along to the evening free of judgement to the safe space.

Follow this link:
GoFundMe set up for East Lothian transwoman's breast augmentation raises over 700 in 24 hours - Edinburgh News

Posted in Hormone Replacement Therapy | Comments Off on GoFundMe set up for East Lothian transwoman’s breast augmentation raises over 700 in 24 hours – Edinburgh News

Testosterone Replacement Therapy Market Insights with Latest Statistics and Growth Prediction to 2026 | AbbVie, Endo International, Eli lilly, Pfizer,…

Posted: March 4, 2020 at 9:45 am

The Testosterone Replacement Therapy Market report draws accurate insights by examining the latest and prospective industry trends, helping the readers recognize the products and services that are boosting revenue growth and profitability. The study performs a detailed analysis of all the significant factors impacting the market on a global and regional scale, including drivers, constraints, threats, challenges, prospects, and industry-specific trends. Additionally, the report cites worldwide certainties and endorsements, along with a downstream and upstream evaluation of leading participants.

To ask for a sample copy of the Testosterone Replacement Therapy Market Report, visit:https://www.reportsanddata.com/sample-enquiry-form/229

Scope of the Report:

The report focuses on the important geographies of sale of the Testosterone replacement therapy such as North America, Europe and Asia-Pacific, South America, Middle East and Africa. The entire testosterone replacement therapy market has been categorized into three segments in this report, namely- manufacturers, regions, type and application.

Reasons to Buy the Report:

For the purpose of this report, Reports and Data has segmented the Testosterone Replacement Therapy market on the basis of type, source, animal, application, and region:

In market segmentation by types of testosterone replacement therapies, the report covers

Get Discounts on the Testosterone Replacement Therapy Market Report at:https://www.reportsanddata.com/discount-enquiry-form/229

In market segmentation by applications of the testosterone replacement therapy, the report covers the following uses

Regional Outlook (Revenue in USD Million; 20162026)

Key highlights of the Testosterone Replacement Therapy market:

The report is distributed over 15 Chapters to display the analysis of the global Testosterone Replacement Therapy market.

Chapter 1 covers the Blow-Fill-Seal (BFS) technology product Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2 talks about the top manufacturers and analyses their sales, revenue and pricing decisions for the duration 2016 and 2017;

Chapter 3 displays the competitive nature of the market by discussing the competition among the top manufacturers. It dissects the market using sales, revenue and market share data for 2016 and 2017;

Chapter 4, shows the global market by regions and the proportionate size of each market region based on sales, revenue and market share of Blow-Fill-Seal (BS) technology product, for the period 2012- 2017;

Chapter 5, 6, 7, 8 and 9, are dedicated to the analysis of the key regions, with sales, revenue and market share by key countries in these regions;

Browse Table of Contents with Facts and Figures of Testosterone Replacement Therapy Market Report at: https://www.reportsanddata.com/report-detail/global-testosterone-replacement-therapy-market-by-manufacturers-countries-type-and-application-forecast-to-2022

We are grateful to you for reading our report. If you wish to find more details of the report or want a customization, contact us. You can get a detailed information of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Continued here:
Testosterone Replacement Therapy Market Insights with Latest Statistics and Growth Prediction to 2026 | AbbVie, Endo International, Eli lilly, Pfizer,...

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market Insights with Latest Statistics and Growth Prediction to 2026 | AbbVie, Endo International, Eli lilly, Pfizer,…

Key Emerging Trends in Testosterone Replacement Therapy Market 2020 | AbbVie, Endo International, Eli lilly, Pfizer, Others – Feed Road

Posted: March 4, 2020 at 9:45 am

The Testosterone Replacement Therapy Market report draws accurate insights by examining the latest and prospective industry trends, helping the readers recognize the products and services that are boosting revenue growth and profitability. The study performs a detailed analysis of all the significant factors impacting the market on a global and regional scale, including drivers, constraints, threats, challenges, prospects, and industry-specific trends. Additionally, the report cites worldwide certainties and endorsements, along with a downstream and upstream evaluation of leading participants.

To ask for a sample copy of the Testosterone Replacement Therapy Market Report, visit:https://www.reportsanddata.com/sample-enquiry-form/229

Breadth of the Report:

The report focuses on the important geographies of sale of the Testosterone replacement therapy such as North America, Europe and Asia-Pacific, South America, Middle East and Africa. The entire testosterone replacement therapy market has been categorized into three segments in this report, namely- manufacturers, regions, type and application.

Reasons to Buy the Report:

For the purpose of this report, Reports and Data has segmented the Testosterone Replacement Therapy market on the basis of type, source, animal, application, and region:

In market segmentation by types of testosterone replacement therapies, the report covers

Get Discounts on the Testosterone Replacement Therapy Market Report at:https://www.reportsanddata.com/discount-enquiry-form/229

In market segmentation by applications of the testosterone replacement therapy, the report covers the following uses

Regional Outlook (Revenue in USD Million; 20162026)

Key highlights of the Testosterone Replacement Therapy market:

The report is distributed over 15 Chapters to display the analysis of the global Testosterone Replacement Therapy market.

Chapter 1 covers the Blow-Fill-Seal (BFS) technology product Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2 talks about the top manufacturers and analyses their sales, revenue and pricing decisions for the duration 2016 and 2017;

Chapter 3 displays the competitive nature of the market by discussing the competition among the top manufacturers. It dissects the market using sales, revenue and market share data for 2016 and 2017;

Chapter 4, shows the global market by regions and the proportionate size of each market region based on sales, revenue and market share of Blow-Fill-Seal (BS) technology product, for the period 2012- 2017;

Chapter 5, 6, 7, 8 and 9, are dedicated to the analysis of the key regions, with sales, revenue and market share by key countries in these regions;

Browse Table of Contents with Facts and Figures of Testosterone Replacement Therapy Market Report at: https://www.reportsanddata.com/report-detail/global-testosterone-replacement-therapy-market-by-manufacturers-countries-type-and-application-forecast-to-2022

We are grateful to you for reading our report. If you wish to find more details of the report or want a customization, contact us. You can get a detailed information of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Original post:
Key Emerging Trends in Testosterone Replacement Therapy Market 2020 | AbbVie, Endo International, Eli lilly, Pfizer, Others - Feed Road

Posted in Testosterone Replacement Therapy | Comments Off on Key Emerging Trends in Testosterone Replacement Therapy Market 2020 | AbbVie, Endo International, Eli lilly, Pfizer, Others – Feed Road

How high testosterone levels have different health outcomes for men and women – Health24

Posted: March 4, 2020 at 9:45 am

High levels of the sex hormone testosterone may trigger different health problems in men and women, a new study reveals.

In women, testosterone may increase the risk for type 2 diabetes, while in men it lowers that risk. But high levels of testosterone increase the risk for breast and endometrial cancer in women and prostate cancer in men, the researchers reported.

"Our findings provide unique insights into the disease impacts of testosterone. In particular, they emphasize the importance of considering men and women separately in studies, as we saw opposite effects for testosterone on diabetes," said lead researcher Katherine Ruth, of the University of Exeter in the United Kingdom.

"Caution is needed in using our results to justify use of testosterone supplements until we can do similar studies of testosterone with other diseases, especially cardiovascular disease," Ruth explained in a University of Cambridge news release.

Dr Joel Zonszein, an emeritus professor of medicine at Albert Einstein College of Medicine in New York City, said there is a "sweet spot" of normal values for men and women. "Too much is not good, and too little is also bad," he explained.

"Testosterone supplementation is widely used in both men and women with normal values with no good evidence of benefit. Testosterone replacement in truly deficient individuals is something else," said Zonszein, who had no role in the study.

For the study, British researchers collected genetic data on more than 425 000 men and women listed in the UK Biobank. The investigators found more than 2 500 genetic variations associated with levels of testosterone and the protein that binds it sex hormone-binding globulin.

The researchers checked their results with analyses of other relevant studies and used a randomisation method to see if associations between testosterone and disease are causal.

In women, a high level of testosterone was tied to a 37% increased risk for type 2 diabetes and a 51% increased risk for polycystic ovary syndrome.

In men, however, a high testosterone level was linked to a 14% lower risk of developing type 2 diabetes, the findings showed.

"The findings in men that higher testosterone has a protective effect and reduces the risk of type 2 diabetes is news to me," Zonszein said. "This needs to be shown by other studies and its mechanism needs to be elucidated."

Dr Minisha Sood, an endocrinologist at Lenox Hill Hospital in New York City, said that testosterone may not be as protective in women because it converts to estradiol, which is related to the risk for breast cancer.

"High levels of testosterone in women have also been shown to increase visceral fat, which is linked to the components of metabolic syndrome," Sood said.

That men with high testosterone are at lower risk of developing type 2 diabetes is likely related to having more lean muscle mass, which improves insulin sensitivity and reduces the likelihood of type 2 diabetes, she said.

But Sood isn't a fan of men using testosterone supplements to ward off diabetes.

"Testosterone therapy comes with potential risks, including a high red blood cell count and higher rates of high-grade prostate cancer if a man is already predisposed to develop prostate cancer," she said.

Obese men or those with type 2 diabetes would benefit more from lifestyle changes to improve testosterone levels, namely, weight loss, healthy diet and exercise.

"This approach is preferred in that population over testosterone replacement whenever possible," Sood said.

The report was published in the journal Nature Medicine.

Image credit: iStock

See the rest here:
How high testosterone levels have different health outcomes for men and women - Health24

Posted in Testosterone Replacement Therapy | Comments Off on How high testosterone levels have different health outcomes for men and women – Health24

SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week – Florida Today

Posted: March 4, 2020 at 9:44 am

FLORIDA TODAY's Rob Landers brings you some of today's top stories on the News in 90 Seconds. Florida Today

Get ready to rumble Friday night. And that's not just because it's Friday and it's time to party.

SpaceX is poised to launch its Falcon 9 rocket and cargo Dragon capsule from Cape Canaveral Air Force Station Launch Complex 40 no earlier than 11:50 p.m. Friday.

From there it will head on a three-day journey to the International Space Station where Dragon will deliver science experiments, cargo and supplies to the crew onboard.

This will mark the aerospace company's 20th flight under NASA's Commercial Resupply Services contract as well as the last time SpaceX uses its Dragon 1 capsule before retiring it to make way to its newer, more advanced spacecraft: Dragon 2.

Autoplay

Show Thumbnails

Show Captions

The newer spacecraft is not only equipped to carry supplies to and from the space station, but it is also certified to refly up to five times (Dragon 1 for instance, was only certified for three re-flights) and can also carry humans, which could happen as soon as May for NASA's Commercial Crew Program.

"Some of the accomplishments of SpaceX under the CRS One program includesthe first U.S. Commercial provider toberth the ISS ... With that we're looking forward to SpaceX continuing on the CRS Two contract with SpaceX-21," said Jennifer Buchli, deputy chief scientist for NASA's International Space Station Program Science Office during a media teleconference.

SpaceX launched a Falcon 9 rocket with cargo for the International Space Station on Thursday, Dec. 5, 2019. Cape Canaveral hosted the liftoff. Florida Today

For this mission, Dragon 1 will deliver several science experiments including:

ACE-T-Ellipsoids: Researchers from the New Jersey Institute of Technology will examine colloids small particles suspended within a fluid in microgravity to not only understand fluid physics more but to advance space-based additive manufacturing, an area of great interest to NASA and other agencies in the U.S.

MVP Cell-03: Emory University School of Medicine will study whether microgravity increases the production of heart cells from specific stem cells, called "human-induced pluripotent stem cells." Those specific cells have the potential to be used toreplenish cells that are damaged or lost due to cardiac diseases.

Flow Chemistry in Microgravity: Researchers from Boston University will study the effects of microgravity on chemical reactions as a step toward on-demand production of chemicals and materials in space.

Droplet Formation Study: Delta Faucet Company will study water droplet formation and water flow in microgravity to gain a better understanding on how to improve its showerhead technology in an effort to create better performance while also conserving water and energy.

Dragon will also deliver the European external payload hosting facility called Bartolomeo that will be an enhancement to the space station's European Columbus Module.

Contact Jaramillo at321-242-3668or antoniaj@floridatoday.com. Follow her onTwitterat@AntoniaJ_11.

Get the latest space news by becoming a subscriber.

Read or Share this story: https://www.floridatoday.com/story/tech/science/space/2020/03/02/spacex-set-launch-falcon-9-rocket-and-dragon-capsule-cape-canaveral/4855497002/

Go here to see the original:
SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today

Posted in New Jersey Stem Cells | Comments Off on SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week – Florida Today

Stem Cell Transplants in Cancer Treatment – National …

Posted: March 3, 2020 at 2:44 am

Stem cell transplants are procedures that restore blood-forming stem cells in people who have had theirs destroyed by the very high doses of chemotherapy or radiation therapy that are used to treat certain cancers.

Blood-forming stem cells are important because they grow into different types of blood cells. The main types of blood cells are:

You need all three types of blood cells to be healthy.

In a stem cell transplant, you receive healthy blood-forming stem cells through a needle in your vein. Once they enter your bloodstream, the stem cells travel to the bone marrow, where they take the place of the cells that were destroyed by treatment. The blood-forming stem cells that are used in transplants can come from the bone marrow, bloodstream, or umbilical cord. Transplants can be:

To reduce possible side effects and improve the chances that an allogeneic transplant will work, the donors blood-forming stem cells must match yours in certain ways. To learn more about how blood-forming stem cells are matched, see Blood-Forming Stem Cell Transplants.

Stem cell transplants do not usually work against cancer directly. Instead, they help you recover your ability to produce stem cells after treatment with very high doses of radiation therapy, chemotherapy, or both.

However, in multiple myeloma and some types of leukemia, the stem cell transplant may work against cancer directly. This happens because of an effect called graft-versus-tumor that can occur after allogeneic transplants. Graft-versus-tumor occurs when white blood cells from your donor (the graft) attack any cancer cells that remain in your body (the tumor) after high-dose treatments. This effect improves the success of the treatments.

Stem cell transplants are most often used to help people with leukemia and lymphoma. They may also be used for neuroblastoma and multiple myeloma.

Stem cell transplants for other types of cancer are being studied in clinical trials, which are research studies involving people. To find a study that may be an option for you, see Find a Clinical Trial.

The high doses of cancer treatment that you have before a stem cell transplant can cause problems such as bleeding and an increased risk of infection. Talk with your doctor or nurse about other side effects that you might have and how serious they might be. For more information about side effects and how to manage them, see the section on side effects.

If you have an allogeneic transplant, you might develop a serious problem called graft-versus-host disease. Graft-versus-host disease can occur when white blood cells from your donor (the graft) recognize cells in your body (the host) as foreign and attack them. This problem can cause damage to your skin, liver, intestines, and many other organs. It can occur a few weeks after the transplant or much later. Graft-versus-host disease can be treated with steroids or other drugs that suppress your immune system.

The closer your donors blood-forming stem cells match yours, the less likely you are to have graft-versus-host disease. Your doctor may also try to prevent it by giving you drugs to suppress your immune system.

Stem cells transplants are complicated procedures that are very expensive. Most insurance plans cover some of the costs of transplants for certain types of cancer. Talk with your health plan about which services it will pay for. Talking with the business office where you go for treatment may help you understand all the costs involved.

To learn about groups that may be able to provide financial help, go to the National Cancer Institute database, Organizations that Offer Support Services and search "financial assistance." Or call toll-free 1-800-4-CANCER (1-800-422-6237) for information about groups that may be able to help.

When you need an allogeneic stem cell transplant, you will need to go to a hospital that has a specialized transplant center. The National Marrow Donor Program maintains a list of transplant centers in the United States that can help you find a transplant center.

Unless you live near a transplant center, you may need to travel from home for your treatment. You might need to stay in the hospital during your transplant, you may be able to have it as an outpatient, or you may need to be in the hospital only part of the time. When you are not in the hospital, you will need to stay in a hotel or apartment nearby. Many transplant centers can assist with finding nearby housing.

A stem cell transplant can take a few months to complete. The process begins with treatment of high doses of chemotherapy, radiation therapy, or a combination of the two. This treatment goes on for a week or two. Once you have finished, you will have a few days to rest.

Next, you will receive the blood-forming stem cells. The stem cells will be given to you through an IV catheter. This process is like receiving a blood transfusion. It takes 1 to 5 hours to receive all the stem cells.

After receiving the stem cells, you begin the recovery phase. During this time, you wait for the blood cells you received to start making new blood cells.

Even after your blood counts return to normal, it takes much longer for your immune system to fully recoverseveral months for autologous transplants and 1 to 2 years for allogeneic or syngeneic transplants.

Stem cell transplants affect people in different ways. How you feel depends on:

Since people respond to stem cell transplants in different ways, your doctor or nurses cannot know for sure how the procedure will make you feel.

Doctors will follow the progress of the new blood cells by checking your blood counts often. As the newly transplanted stem cells produce blood cells, your blood counts will go up.

The high-dose treatments that you have before a stem cell transplant can cause side effects that make it hard to eat, such as mouth sores and nausea. Tell your doctor or nurse if you have trouble eating while you are receiving treatment. You might also find it helpful to speak with a dietitian. For more information about coping with eating problems see the booklet Eating Hints or the section on side effects.

Whether or not you can work during a stem cell transplant may depend on the type of job you have. The process of a stem cell transplant, with the high-dose treatments, the transplant, and recovery, can take weeks or months. You will be in and out of the hospital during this time. Even when you are not in the hospital, sometimes you will need to stay near it, rather than staying in your own home. So, if your job allows, you may want to arrange to work remotely part-time.

Many employers are required by law to change your work schedule to meet your needs during cancer treatment. Talk with your employer about ways to adjust your work during treatment. You can learn more about these laws by talking with a social worker.

Read the original:
Stem Cell Transplants in Cancer Treatment - National ...

Posted in Stem Cell Therapy | Comments Off on Stem Cell Transplants in Cancer Treatment – National …

Page 1,111«..1020..1,1101,1111,1121,113..1,1201,130..»